GenMark Diagnostics receives FDA clearance for BCID-GN Panel

|About: GenMark Diagnostics, Inc. (GNMK)|By:, SA News Editor

The FDA has granted FDA 510(k) market clearance to GenMark Diagnostics (NASDAQ:GNMK) for its ePlex Blood Culture Identification Gram-Negative (BCID-GN) Panel.

The ePlex BCID Panels provide broad coverage of organisms and resistance markers that can lead to sepsis, including anaerobes and multidrug resistant organisms, as well as common and emerging fungal pathogens.

Subscribe for full text news in your inbox